Research progress in MCM family: Focus on the tumor treatment resistance - 22/03/24
Abstract |
Malignant tumors constitute a significant category of diseases posing a severe threat to human survival and health, thereby representing one of the most challenging and pressing issues in the field of biomedical research. Due to their malignant nature, which is characterized by a high potential for metastasis, rapid dissemination, and frequent recurrence, the prevailing approach in clinical oncology involves a comprehensive treatment strategy that combines surgery with radiotherapy, chemotherapy, targeted drug therapies, and other interventions. Treatment resistance remains a major obstacle in the comprehensive management of tumors, serving as a primary cause for the failure of integrated tumor therapies and a critical factor contributing to patient relapse and mortality. The Minichromosome Maintenance (MCM) protein family comprises functional proteins closely associated with the development of resistance in tumor therapy.The influence of MCMs manifests through various pathways, encompassing modulation of DNA replication, cell cycle regulation, and DNA damage repair mechanisms. Consequently, this leads to an enhanced tolerance of tumor cells to chemotherapy, targeted drugs, and radiation. Consequently, this review explores the specific roles of the MCM family in various cancer treatment strategies. Its objective is to enhance our comprehension of resistance mechanisms in tumor therapy, thereby presenting novel targets for clinical research aimed at overcoming resistance in cancer treatment. This bears substantial clinical relevance.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Elucidating the significant role of MCM family genes in tumor therapy resistance. |
• | MCM family genes promote the tumor therapy resistance by enhancing DNA damage repair. |
• | MCM family genes regulate the cell cycle, leading to the formation of tumor therapy resistance. |
• | MCM family genes hold application prospects in targeted therapy. |
Keywords : MCM family genes, Tumor treatment resistance, DNA damage repair, DNA replication, Cell cycle arrest, Epithelial-mesenchymal transition
Plan
Vol 173
Article 116408- avril 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?